We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

117 hedge funds and large institutions have $85.2M invested in Sanofi Contingent Value Rights in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 35 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 117 → 117 (0)

38% less capital inflows, than outflows

Capital inflows: $3.82M | Capital outflows: $6.18M

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

63% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 35

Holders
117
Holders Change
–
Holders Change %
0%
% of All Funds
3.11%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
8
Increased
13
Reduced
35
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

GCVRZ Hedge Fund Activity: Q4 2014 in Review

117 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2014, worth a combined $85.2M — up 64% from $52M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of GCVRZ and 8 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 13 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.4M. The largest seller was Gruss Capital Management, cutting an estimated $3.02M.

  • 117 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $85.2M of Sanofi Contingent Value Rights stock for Q4 2014, up 64% quarter-over-quarter.
  • 8 funds opened new Sanofi Contingent Value Rights positions in Q4 2014 and 14 closed out, a net change of -6 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2014 was Oxford Asset Management, an estimated $2.4M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2014 was Gruss Capital Management, an estimated $3.02M sold.

Based on aggregated 13F filings for Q4 2014.